AbTis wins US patent challenge from Anjinmoto

AbTis, a South Korean biotechnology company developing antibody-drug conjugate technologies, said the US Patent Trial and Appeal Board has upheld its US patent covering the company’s exclusive AbClick platform.

The review was initiated by Anjinmoto, which asserted that the patent failed to meet US requirements for written description, enablement and definiteness under Section 112 of the US Patent Act.

They also claimed challenges based on anticipation under Section 102 and obviousness under Sect